UK markets closed
  • FTSE 100

    7,486.67
    +20.07 (+0.27%)
     
  • FTSE 250

    19,545.70
    +5.36 (+0.03%)
     
  • AIM

    847.07
    +2.68 (+0.32%)
     
  • GBP/EUR

    1.1629
    -0.0005 (-0.04%)
     
  • GBP/USD

    1.2091
    -0.0023 (-0.19%)
     
  • BTC-GBP

    13,718.32
    +60.55 (+0.44%)
     
  • CMC Crypto 200

    386.97
    +4.32 (+1.13%)
     
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • DOW

    34,347.03
    +152.97 (+0.45%)
     
  • CRUDE OIL

    76.28
    -1.66 (-2.13%)
     
  • GOLD FUTURES

    1,754.00
    +8.40 (+0.48%)
     
  • NIKKEI 225

    28,283.03
    -100.06 (-0.35%)
     
  • HANG SENG

    17,573.58
    -87.32 (-0.49%)
     
  • DAX

    14,541.38
    +1.82 (+0.01%)
     
  • CAC 40

    6,712.48
    +5.16 (+0.08%)
     

Liquid Biopsy Global Market Report 2022: Increased Government Funding for Cancer Detection Drives Growth

Company Logo
Company Logo

Global Liquid Biopsy Market

Global Liquid Biopsy Market
Global Liquid Biopsy Market

Dublin, Nov. 15, 2022 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Global Market Report 2022, By Product, By End User, By Clinical Application" report has been added to ResearchAndMarkets.com's offering.

The global liquid biopsy market is expected to grow from $4.02 billion in 2021 to $5.17 billion in 2022 at a compound annual growth rate (CAGR) of 28.5%. The market is expected to reach $15.01 billion in 2026 at a CAGR of 30.6%.

Government funds for refining cancer detection drive the growth of the liquid biopsy market. Government funds help researchers in drug discovery, diagnosis, and treatment of diseases such as Cancer. For instance, in 2019, National Cancer Institute (NCI), a USA-based government agency gave funds worth $2.1 million and a five-year grant to Translational Genomics Research Institute (TGen), a genomics research institute based in U.S.A.

The funding enables TGen and Mayo Clinic researchers to drive the clinical trials for liquid biopsy test for the detection of breast cancer. The National Cancer Institute (NCI) aims to post a Funding Opportunity Announcement (FOA) in December 2020 to enable applications for cancer diagnosis, prevention, identification and treatment innovations for public health (U01 activity code). The FAO has projected that the overall funding is expected to hit $4 million in the fiscal year 2022. Therefore, government funds positively impact the growth of liquid biopsy market.

Unclear regulations on laboratory developed tests (LDT) for liquid biopsy have always been a major challenge in the liquid biopsy market. A laboratory developed test (LDT) is an in-vitro diagnostic test (IVD) intended for clinical use that is designed, manufactured to be used in a single laboratory. For instance, in 2019, the Food and Drug Administration (FDA) proposed a plan to increase the regulations for the approval of laboratory developed tests.

However, the regulations are unclear and do not reduce the time it takes for the approval of these tests. Following this, the FDA, till 2019, has approved only two liquid biopsy tests. The first test which identifies EGFR mutations in NSCLC patients was approved in 2016 while the second test for detecting the PIK3CA mutation in patients was approved in 2019. Such delays in the approval of liquid biopsy tests by the FDA are expected to have a negative impact on the liquid biopsy market.

Companies are rapidly adopting new market dynamics and focusing primarily on new product launches, to meet the ever-increasing need for liquid biopsy products and services, to increase their revenue and also for gaining a competitive edge over their rivals.

For instance, In August 2020, Personalis, Inc., a USA based advanced cancer genomics company, revealed the introduction of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling device that uses blood samples from innovative solid tumour cancer patients. NeXT Liquid Biopsy, combined with Personalis' leading immunoid NeXT tissue profiling tool, allows a more detailed immuno-genomics image of the tumour which can now be tracked over time from blood samples.

These abilities can enable biopharmaceutical businesses improve their knowledge of tumour biology, specifically resistance mechanisms, to help create next-generation cancer therapies. Thus, companies are investing in the development of new products in the liquid biopsy market.

Scope

Markets Covered:
1) By Technique: Ultrasound; MRI; X-ray; Computed Tomography; Others
2) By Application: Oncology; Cardiology; Orthopedic; Others
3) By End User: Diagnostic Centers; Hospitals; Research Centers

Key Topics Covered:

1. Executive Summary

2. Liquid Biopsy Market Characteristics

3. Liquid Biopsy Market Trends And Strategies

4. Impact Of COVID-19 On Liquid Biopsy

5. Liquid Biopsy Market Size And Growth

6. Liquid Biopsy Market Segmentation

7. Liquid Biopsy Market Regional And Country Analysis

8. Asia-Pacific Liquid Biopsy Market

9. China Liquid Biopsy Market

10. India Liquid Biopsy Market

11. Japan Liquid Biopsy Market

12. Australia Liquid Biopsy Market

13. Indonesia Liquid Biopsy Market

14. South Korea Liquid Biopsy Market

15. Western Europe Liquid Biopsy Market

16. UK Liquid Biopsy Market

17. Germany Liquid Biopsy Market

18. France Liquid Biopsy Market

19. Eastern Europe Liquid Biopsy Market

20. Russia Liquid Biopsy Market

21. North America Liquid Biopsy Market

22. USA Liquid Biopsy Market

23. South America Liquid Biopsy Market

24. Brazil Liquid Biopsy Market

25. Middle East Liquid Biopsy Market

26. Africa Liquid Biopsy Market

27. Liquid Biopsy Market Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions In The Liquid Biopsy Market

29. Liquid Biopsy Market Future Outlook and Potential Analysis

30. Appendix

Companies Mentioned

  • Qiagen N.V.

  • Roche Diagnostics

  • Bio-Rad Laboratories Inc.

  • Myriad Genetics Inc.

  • Guardant Health Inc.

  • Thermo Fisher Scientific

  • Guardant Health

  • Menarini Silicon Biosystems

  • Biocept Inc.

  • F. Hoffmann-La Roche AG

  • Janssen Diagnostics LLC.

  • Trovagene Inc.

  • Fraunhofer-Gesellschaft

  • MDX Health SA

  • Agilent Technologies Inc.

  • Cygnus Biosciences

  • Illumina Inc.

  • Oxford Nanopore

  • Quantum Biosystems

For more information about this report visit https://www.researchandmarkets.com/r/rcjqws

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900